TVM III

TVM Capital Life Science is a leading international venture capital firm focused on the life sciences sector, with a significant presence in Munich and Montreal. The firm is distinguished by its unique "Project-Focused Company" (PFC) investment model, which involves creating single-asset companies to develop early-stage therapeutics to clinical proof-of-concept, often in collaboration with strategic partners like Eli Lilly. In addition to its early-stage PFC strategy, TVM invests in late-stage therapeutics and commercial-stage medical technologies, diagnostics, and digital health companies. With over 35 years of experience and more than $900 million in assets under management, TVM has a long track record of building and exiting successful healthcare companies. The firm's dual-pronged strategy aims to maximize capital efficiency and provide clear exit paths through trade sales to pharmaceutical players.